China Pharma Desk
  • Home
  • Desk brief
  • Desk analysis
  • Deals & BD
  • Regulation
  • Market Access
  • Pipeline
  • Capital
  • Start Here
  • Glossary
  • About
  • Contact
Sign in Subscribe

Market Access

NRDL reimbursement negotiations, volume-based procurement (VBP), hospital formulary listing, and provincial pricing.
China commercialization timeline for Abbisko and Merck KGaA's Beijiemai (pimicotinib): Dec 2025 NMPA approval, hospital launch, and open NRDL access

Reading China’s TGCT market through Beijiemai: hospitals first, reimbursement still open

China approved Abbisko’s CSF-1R inhibitor Beijiemai (pimicotinib, 02256.HK) first and Merck KGaA launched in tertiary hospitals, while list price and NRDL status remain open.
Lin Yi 12 Nov 2026

Subscribe to China Pharma Desk

Get the Desk brief by email—same-day notes on China’s pharma industry.
  • Start Here (Guide)
  • China Pharma Glossary
  • About & Editorial Policy
  • RSS Feed
  • AI Index (llms.txt)
China Pharma Desk © 2026. Powered by Ghost